Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report 230701-230930

Press Release November 16, 2023 Revenue and Result Scandinavian Real Heart AB is working with research and development and currently has no sales of any products. The income reported for the period consists mainly of foreign currency exchange gains. Research and development costs of Realheart® TAH were capitalized during Q3 with 4.2 MSEK. 1.9 MSEK for purchased services and other external costs and 2.3 MSEK for personnel. During the period, write-downs of capitalized costs for research and development were made by 0 MSEK. Other external costs of 8.9 MSEK includes cost for

Metso issues first EUR 300 million sustainability linked bond

Metso Corporation's press release on November 16, 2023 at 9.10 a.m. EETNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR SUCH OTHER COUNTRIES OR OTHERWISE IN SUCH CIRCUMSTANCES IN WHICH THE OFFERING OF THE NOTES OR THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.  Metso has successfully issued its first sustainability linked bond under the EMTN (Euro Medium Term Note) programme. The EUR 300 million bond will mature in November 2030, and pay a fixed coupon of 4.375%, subject to an increase in the rate if

Dignitana AB Publishes Q3 2023 Interim Report

19% growth and cost reduction creates another quarter of positive EBITDAFinancial highlights Q3 2023 · Net sales amounted to 22.2 MSEK (18.6), an increase of 19 percent over the same period in 2022. · Operating result amounted to-3.1 MSEK (-3.6). · Net result after financial items amounted to-3.7 MSEK (-3.7). · EBITDA for the Third Quarter is positive at 674 TSEK (-119). · Earnings per share were-0.05 SEK (-0.06). · Cash Balance amounted to 7.0 MSEK (6.7).  · Average Daily Treatment Revenue (ADTR)* was 237 TSEK (203), an increase of 17 percent over the same period in

Beyond Frames secures license agreement for one of the world’s highest-grossing media franchises

Stockholm, November 16, 2023 - Today, Beyond Frames Entertainment announced that they secured a license agreement with a yet-to-be-named, global media and entertainment conglomerate to develop a VR action title for one of the biggest entertainment franchises in the world. The game will be developed by Beyond Frames Entertainment’s wholly-owned subsidiary, Cortopia Studios, and published by Beyond Frames. The project will be partially funded by Beyond Frames who are looking to secure additional project funding for the production.  “Our goal with this title is to bring the massive

Interim Report for 3rd Quarter 2023

Q3 2023: Revenues increased 21.55%, EBIT increased 47.64%. First 9 months 2023: Revenue increased 25.47%, EBIT increased 547.76%Key Facts for the 3[rd] Quarter 2023 (1[st] July 2023 – 30[th] September 2023) Revenues increased 21.55% and EBIT increased 47.64% in the 3[rd] quarter All figures are compared to the same quarter of last year if not explicitly stated otherwise · Revenues increased by 21.55% to €10,326,599 (€8,495,464). · EBIT increased by 47.64% to €1,093,543 (€740,675). · EBIT margin of 10.59 % (8.72%). · Customer deposits increased by 10.94% to €18,515,913 (

Gradientech: Interim report 1 January–30 September 2023

Gradientech AB (publ) interim report for Q3 2023 is now available on the company's website www.gradientech.se.Third quarter 2023 · Net sales amounted to SEK 53 thousand (153). · Net profit/loss amounted to SEK -10,968 thousand (-11,640). · Earnings per share before and after dilution were SEK -0.62 (-0.73). · Cash flow from operating activities amounted to SEK -13,435 thousand (-10,706). · Cash and cash equivalents amounted to SEK 25,873 thousand (41,012) as of September 30, 2023. · Equity amounted to SEK 40,894 thousand (49,216) as of September 30, 2023. January–

Higher provisions for future reclamation of Aitik and Garpenberg

Due to more extensive reclamation plans for Aitik and Garpenberg, Boliden's provisions for reclamation are increased by SEK 3.8 billion. As a result, annual depreciation increases by approximately SEK 200 million and the financial net is negatively affected by approximately SEK 100 million starting in 2024. The result for the fourth quarter of 2023 is not affected. The cash flow impact due to reclamation work mainly only occurs when mines are closed.Most of the extended provisions for reclamation are related to Aitik soon will submit a new application for an operating permit. In connection

BPC Instruments reports results for the period January—September 2023

BPC Instruments (“BPC” or “the Company”) hereby publishes the interim report for the period January 1— September 30, 2023. The interim report is available as an attached file to this release and on the Company’s website (bpcinstruments.com/financial-reports). Below is a summary of the report.CEO Jing Liu comments: ”I’m pleased to present our Q3 2023 report for BPC Instruments. This quarter, we’ve sustained the exceptional momentum from the first half of the year. Our Q3 net sales amounted to KSEK 13,839, representing a 60 percent increase from the same period last year. Additionally, our

Interim report for the period 1 January – 30 September 2023

Cinis Fertilizer secures growth plan through supply agreement and establishment in the USA Cinis Fertilizer’s circular business model creates value for a broad group of stakeholders and with growing global interest, new markets are opening up. At the end of September, the company signed a supply agreement with Ascend Elements, a leading American manufacturer of battery materials, and a letter of intent with K+S, a global player in salts, for the supply of potassium chloride and the sale of all production of potassium sulphate. There are thus the conditions for the company to establish

New modular Metso HRT-S high rate thickening solution shortens lead times significantly

Metso Corporation’s press release on November 16, 2023, at 09:00 a.m. EETMetso is launching a pre-engineered high-rate thickening solution, the HRT-S, which will allow significantly shorter delivery times. The HRT-S complements Metso’s existing High-Rate Thickener product family which consists of the HRT and HRT-S products. The HRT-S thickener is a part of Metso’s Planet Positive  offering, enabling savings in power consumption, reduction in embedded carbon and decreased maintenance costs. “Built upon the

Fractal Gaming Group Interim Report January-September 2023

Third quarter 2023 · Net sales amounted to SEK 189.9 million (131.0). · Product profit amounted to SEK 79.3 million (50.2), with a product margin of 41.8% (38.3). · EBITDA amounted to SEK 35.1 million (12.5), corresponding to an EBITDA margin of 18.5% (9.5). · EBIT amounted to SEK 29.8 million (7.5), corresponding to an EBIT margin of 15.7% (5.7). · Operating cash flow amounted to SEK 65.0 million (12.2). · Interest-bearing net debt was SEK -75.5 million (126.0). · Earnings per share amounted to SEK 0.8 (0.2). · No items affecting comparability for the quarter.

ZINZINO AB (PUBL): INTERIM REPORT THIRD QUARTER 2023

GOING TOWARDS RECORD RESULTS IN 2023 AFTER ANOTHER VERY STRONG QUARTER The total revenues during the third quarter of 2023 amounted to SEK 436.9 (349.9) million, which corresponded to 25% (12%) growth compared to the corresponding quarter of the previous year. The EBITDA result increased to SEK 71.2 (25.4) million for the quarter and the EBITDA margin increased to 16.3% (7.3%). As before, behind the margin improvement are primarily changes in the sales mix, efficiencies and economies of scale. During the quarter, a very successful sales launch was carried out in Mexico and BalanceTest no.

Millions to lose sight of spending as monthly subscriptions and payment deferrals pile pressure on household finances

· Almost half (45%) of European consumers are caught out by the build-up of monthly subscription costs · Generation gap means over half (52%) of millennials and 53% of Gen Z struggle to keep track of subscription spending, compared with 34% of Baby boomers · 30% of consumers are planning to increase their use of buy-now-pay-later products · Three in four (76%) are just breaking even or are over-spending each month, with the average over-spender exceeding their budget by EUR 232 · One in five consumers have no ‘cash buffer’ to fall back on in the event of difficultiesMillions of

Genetic Analysis – Capital raise give boost – Mangold Insight Analysis

Genetic Analysis, a diagnostic company within Life Science, is growing rapidly. To continue its expansion, the company needs to raise capital, expected to be done in several steps. First, in a direct issue to a group of existing shareholders, followed by a repair rights issue directed to existing shareholders. Its partner in China, is also expected to invest in the company early next year. In total, the company is expected to be able to raise up to NOK 25 million. This enables continued growth that will take the company to profitability.The third quarter was soft due to earlier stock-

SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

STOCKHOLM, SWEDEN, - November 16, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations. The Skin and Cancer Institute is a world-renowned dermatology practice group of dermatologists and skin cancer surgeons, and will be the first dermatology practice group in California to bring AI-driven technology to their patients for skin cancer detection. With more

Metsä Group’s insect damage application awarded as the best innovation in Finland

An artificial intelligence application developed by Metsä Group and CollectiveCrunch for detecting insect damage in forests has won the Quality Innovation Award in a competition organised by the Finnish Quality Association, Excellence Finland. Metsä Group’s Future Sawmill concept won the Business Innovation category of the competition. The Finnish Quality Association presented the awards on Wednesday 15 November. The award-winning application from Metsä Group and CollectiveCrunch detects insect damage in forests such as damage caused by spruce bark beetles before it is visible to the

Höegh LNG: Interim results for the quarter ended 30 September 2023

Hamilton, Bermuda, 16 November 2023 - Höegh LNG Holdings Ltd. ("Höegh LNG") today reports its interim financial results for the quarter ended 30 September 2023. The group reported a total income of USD 140 million and an EBITDA of USD 89 million for the third quarter of 2023, compared to USD 127 million and USD 79 million for the preceding quarter.Furthermore, in the third quarter Höegh LNG entered into a strategic partnership with Aker BP to develop a fully comprehensive carbon transport and storage (CCS) offering for industrial CO2 emitters in Northern Europe.  Subsequent to the

Half-year Report

16 November 2023   PHSC PLC (“PHSC”, the “Company” or the “Group”)   Unaudited Interim Results for the six months ended 30 September 2023   PHSC (AIM: PHSC), a leading provider of health, safety, hygiene and environmental consultancy services and security solutions to the public and private sectors, is pleased to announce its unaudited interim results for the six-month period ended 30 September 2023.   GROUP CHIEF EXECUTIVE OFFICER’S STATEMENT   Financial Highlights · Group revenue of £1.651m (H1 FY23: £1.679m). · EBITDA of £174k (H1 FY23: £162k).

Key results of Sedana Medical’s paediatric study IsoCOMFORT published

Sedana Medical AB (publ) today announces that the main results from the paediatric IsoCOMFORT study have been published in the Clinical Trials Registry EudraCT.IsoCOMFORT was a randomised active-controlled assessor-blinded study comparing the efficacy and safety of sedation with inhaled isoflurane, administered via the company’s medical device Sedaconda ACD-S, with intravenous midazolam in mechanically ventilated paediatric patients 3 to 17 years old. The primary endpoint was to compare the time that the targeted sedation depth was maintained. Key secondary endpoints included opioid

Implantica’s RefluxStop[TM] health economic research, showing superior cost-effectiveness, has received top-recognition at ISPOR, the world’s leading European Health-Economics Conference

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, presented an abstract on cost-effectiveness analysis in Sweden, which was recognized among the Top 5% Posters category for its high scientific quality at the ISPOR Europe conference 2023 (International Society for Pharmacoeconomics and Outcomes Research) in Copenhagen, Denmark.The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options. The

Transcom Holding AB (publ): Third quarter report 2023

Third quarter 2023 highlights · Revenue increased to 180.6M€ (177.5) · EBITDA excluding non-recurring items increased to 25.1M€ (23.0) · EBITDA margin excluding non-recurring items increased to 13.9% (13.0%) · Operating cash flow decreased to 9.4M€ (12.2) · Net debt/EBITDA decreased to 3.5 (3.7) January – September 2023 · Revenue increased to 548.2M€ (525.9) · EBITDA excluding non-recurring items increased to 70.6M€ (62.9) · EBITDA margin excluding non-recurring items increased to 12.9% (12.0%) · Operating cash flow increased to 33.1M€ (27.5) · Net debt/

GomSpace reports a strong improvement in the free cash flow for the third quarter of 2023

In the Q3 2023 interim report, GomSpace reports a strong progress of the financial turnaround as free cash flow is improved with T.SEK 36.095 compared to the first quarter this year. In addition, the company projects full year revenue to reach highest level since the company was founded.GomSpace Group AB (the “Company”) announces its interim report for the third quarter of 2023. HighlightsThird quarter 2023 (2022) · Order intake was T.SEK 39,011 (52,639) · Net revenues increased significantly by 274% to T.SEK 67,706 (18,102) · Gross margin increased to 15% (negative 298%)

UNION therapeutics A/S completes patient enrollment for ADESOS Phase 2b study of orismilast in patients with atopic dermatitis

· Topline results are expected in the first half of 2024 · Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the developed world and a significant unmet medical need exists for safe oral treatments · Orismilast is a next-generation, high potency PDE4 B/D selective inhibitor with recently reported positive Phase 2 results in psoriasis and hidradenitis suppurativa (HS)   Hellerup, Denmark, November 16, 2023 – UNION therapeutics A/S (UNION), a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious

There are no items matching the current filter
There are no more items matching the current filter
Back to top